Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GeneDx Holdings Corp.
Report date July 01, 2022 · Filed April 28, 2023
Section 16 reporting ended · disclosed 2023-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 23,291 |
Ending reported balance
After 2022-07-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-01 · Exercise / conversion · Acquired 5,139 · Balance 25,482 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Row 2 · 2022-07-05 · Sale · Disposed 2,191 · Balance 23,291 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.215 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 77,097 |
Reported balance
After 2022-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-01 · Exercise / conversion · Disposed 5,139 · Balance 77,097 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.215 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2022 Filed Aug 26, 2022 23:30 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 3,473 | $1.20 | $4,167.60 |
DisclosureSEC source: 0001209191-22-047761 · doc4.xml · nonDerivative · entry 2 Miao Richard · CIK 0001934925 · Former Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,867 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 23:30 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 7,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047761 · doc4.xml · derivative · entry 3 Miao Richard · CIK 0001934925 · Former Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,967 Underlying: Class A Common Stock · 7,997 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on October 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on October 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 23:30 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 7,997 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-047761 · doc4.xml · nonDerivative · entry 1 Miao Richard · CIK 0001934925 · Former Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| July 05, 2022 Filed Apr 28, 2023 21:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 2,191 | $1.32 | $2,889.27 |
DisclosureSEC source: 0001209191-23-026072 · doc4.xml · nonDerivative · entry 2 Miao Richard · CIK 0001934925 · Former Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,291 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.215 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2022 Filed Apr 28, 2023 21:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 5,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026072 · doc4.xml · derivative · entry 3 Miao Richard · CIK 0001934925 · Former Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,097 Underlying: Class A Common Stock · 5,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Apr 28, 2023 21:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 5,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026072 · doc4.xml · nonDerivative · entry 1 Miao Richard · CIK 0001934925 · Former Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.